Population-based patterns of treatment and survival for patients with stage I and II non-small cell lung cancer aged 65-74 years and 75 years or older

Elisabeth Driessen*, Deniece Detillon, Gerbern Bootsma, Dirk De Ruysscher, Eelco Veen, Mieke Aarts, Maryska Janssen-Heijnen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Web of Science)
34 Downloads (Pure)

Abstract

Objectives: Insights regarding utilization and survival of surgery and radiotherapy (stereotactic body radiotherapy (SBRT) or conventional radiotherapy (RT)) are lacking for older patients with stage I and II non-small cell lung cancer (NSCLC) in clinical practice.

Methods: Data from the Netherlands Cancer Registry were retrieved for patients >= 65 years with clinical stage I-II NSCLC in 2010-2015. Descriptive analyses, overall survival (OS), and cox regression were stratified for stage I (n = 8742) and II (n = 3439) and compared age groups (65-74 years vs >= 75 years).

Results: Patients aged 65-74 underwent surgery significantly more often compared to those aged >= 75 (stage I 55% vs 27%; stage II: 65% vs 35%), and received SBRT less often (I: 29% vs 42%; II: 5% vs 11%), conventional RT less often (I: 6% vs 11%; II 10% vs 24%) and best supportive care alone less often (BSC, I: 8% vs 19%; II: 9% vs 25%). One-year OS was significantly higher in patients aged 65-74 compared to those aged >= 75 (I: 87% vs 78%; II: 74% vs 60%); as was five-year OS (I: 49% vs 31%; II: 36% vs 18%). After adjustment for gender, histology, stage, treatment, and comorbidity, hazard ratio (HR) of death was higher for patients aged >= 75 compared to those aged 65-74 (1: HR 1.3, 95% confidence interval (CI) 1.1-1.5; II: HR 1.3 95%CI 1.1-1.7).

Conclusion: Patients aged >= 75 with stage I-II NSCLC had poorer OS, underwent surgery less often, and received SBRT, conventional RT, and BSC more often than patients aged 65-74, In both stages, one-year OS within age groups was similar for surgery and SBRT. However, long-term OS adjusted for prognostic factors was superior for surgery compared to SBRT and remained poorer for those aged >= 75. Prospective research should focus on predictive characteristics for treatment selection and patient-centered outcomes. (C) 2019 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)547-554
Number of pages8
JournalJournal of Geriatric Oncology
Volume10
Issue number4
DOIs
Publication statusPublished - Jul 2019
EventGenitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (GU ASCO) - San Francisco, United States
Duration: 14 Feb 201916 Feb 2019

Keywords

  • Non-small cell lung cancer
  • Early stage
  • Stage I
  • Stage II
  • Survival
  • Surgery
  • Radiotherapy
  • SBRT
  • Older patient
  • STEREOTACTIC ABLATIVE RADIOTHERAPY
  • BODY RADIATION-THERAPY
  • ELDERLY-PATIENTS
  • CLINICAL-TRIALS
  • FOLLOW-UP
  • SURGERY
  • COMORBIDITY
  • RECURRENCE
  • MANAGEMENT

Cite this